Paratek Advances Timing of Top-Line Data for Phase 3 Community Acquired Bacterial Pneumonia Study to the Second Quarter of 2017 Pharmaceutical Investing
SCYNEXIS Achieves New Development Milestones Reinforcing the Versatility of SCY-078 in Treating Serious Fungal Infections Life Science Investing
Actinium Pharmaceuticals Announces Submission of EU Orphan Designation Application for Actimab-A Life Science Investing
RedHill Biopharma Announces Positive and Unanimous DSMB Recommendation for Continuation of Phase III Study with RHB-104 for Crohn’s Disease Pharmaceutical Investing
GB Sciences Licenses Patent To Develop New Cannabis-Based Therapies For The Treatment Of Heart Disease Pharmaceutical Investing
Dimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application for DTX301 to Treat OTC Deficiency Pharmaceutical Investing
RedHill Biopharma Announces Phase IIa 48-Week Final Results for RHB-104 in Multiple Sclerosis Pharmaceutical Investing
Neuralstem Announces the Closing of $20 Million Strategic Investment from Tianjin Pharmaceutical Group International Holdings Pharmaceutical Investing
Reata Pharmaceuticals Announces Requested Withdrawal of Registration Statement Due to Adverse Market Conditions Pharmaceutical Investing
